Polyclonal antibody therapies for clostridium difficile infection

Antibodies

Volumn 3, Issue 4, 2014, Pages 272-288

  Simon, Michael R ^a,b   Chervin, Stephanie M ^a   Brown, Stephen C ^a  

^a Secretory IgA Inc ^*  (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Clostridium difficile; Monoclonal IgG; Polyclonal IgA; Polyclonal IgG; Secretory IgA; Toxins A and B

Indexed keywords

BOVINE IMMUNOGLOBULIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COHN FRACTION III PRECIPITATE; IMMUNOGLOBULIN A; JACALIN; POLYCLONAL ANTIBODY; RECOMBINANT ANTIBODY; SECRETORY COMPONENT; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; CELL DAMAGE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMAN; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; ORAL IMMUNOTHERAPY; PASSIVE IMMUNIZATION; PHASE 3 CLINICAL TRIAL (TOPIC);

EID: 85106537272     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib3040272     Document Type: Article

References (54)

1. Wilkins, T. D.; Lyerly, D. M. Clostridium difficile testing: After 20 years, still challenging. J. Clin. Microbiol. 2003, 41, 531-534.
2. McFarland, L. V. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008, 5, 40-48.
3. Sunenshine, R. H.; McDonald, L. C. Clostridium difficile-associated disease: New challenges from an established pathogen. Cleve. Clin. J. Med. 2006, 73, 187-197.
4. Shen, E. P.; Surawicz, C. M. The changing face of Clostridium difficile: What treatment options remain? Am. J. Gastroenterol. 2007, 102, 2789-2792.
5. Lowy, I.; Molrine, D. C.; Leav, B. A.; Blair, B. M.; Baxter, R.; Gerding, D. N.; Nichol, G.; Thomas, W. D., Jr.; Leney, M.; Sloan, S.; et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 2010, 362, 197-205.
6. Lyerly, D. M.; Krivan, H. C.; Wilkins, T. D. Clostridium difficile: Its disease and toxins. Clin. Microbiol. Rev. 1988, 1, 1-18.
7. Barroso, L. A.; Wang, S. Z.; Phelps, C. J.; Johnson, J. L.; Wilkins, T. D. Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res. 1990, 18, 4004.
8. Dove, C. H.; Wang, S. Z.; Price, S. B.; Phelps, C. J.; Lyerly, D. M.; Wilkins, T. D.; Johnson, J. L. Molecular characterization of the Clostridium difficile toxin A gene. Infect. Immunol. 1990, 58, 480-488.
9. Sun, X.; Savidge, T.; Feng, H. The Enterotoxicity of Clostridium difficile Toxins. Toxins 2010, 2, 1848-1880.
10. Borriello, S. P. Pathogenesis of Clostridium difficile infection. J. Antimicrob. Chemother. 1998, 41 (Suppl. C), 13-19.
11. Bacon, A. E., 3rd; Fekety, R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn. Microbiol. Infect. Dis. 1994, 18, 205-209.
12. Salcedo, J.; Keates, S.; Pothoulakis, C.; Warny, M.; Castagliuolo, I.; LaMont, J. T.; Kelly, C. P. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997, 41, 366-370.
13. Goodman, J. W. Immunoglobulins I: Structure & Function. In Basic & Clinical Immunology, 5th ed.; Stites, D. P., Stobo, J. D., Fudenberg, H. H., Wells, J. V., Eds.; Lange Medical Publications: Los Altos, CA, USA, 1984; Chapter 4, pp. 30-42.
14. Johnson, S.; Gerding, D. N.; Janoff, E. N. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J. Infect. Dis. 1992, 166, 1287-1294.
15. Delacroix, D. L.; Hodgson, H. J.; McPherson, A.; Dive, C.; Vaerman, J. P. Selective transport of polymeric immunoglobulin A in bile. Quantitative relationships of monomeric and polymeric immunoglobulin A, immunoglobulin M, and other proteins in serum, bile, and saliva. J. Clin. Invest. 1982, 70, 230-241.
16. Delacroix, D. L.; Elkom, K. B.; Geubel, A. P.; Hodgson, H. F.; Dive, C.; Vaerman, J. P. Changes in size, subclass, and metabolic properties of serum immunoglobulin A in liver diseases and in other diseases with high serum immunoglobulin A. J. Clin. Invest. 1983, 71, 358-367.
17. Longet, S.; Miled, S.; Lötscher, M.; Miescher, S. M.; Zuercher, A. W.; Corthésy, B. Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies. J. Biol. Chem. 2013, 288, 4085-4094.
18. Libby, J. M.; Jortner, B. S.; Wilkins, T. D. Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect. Immun. 1982, 36, 822-829.
19. Kink, J. A.; Williams, J. A. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect. Immun. 1998, 66, 2018-2025.
20. Babcock, G. J.; Broering, T. J.; Hernandez, H. J.; Mandell, R. B.; Donahue, K.; Boatright, N.; Stack, A. M.; Lowy, I.; Graziano, R.; Molrine, D.; et al. Human monoclonal antibodies directed against Toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 2006, 74, 6339-6347.
21. Marozsan, A. J.; Ma, D.; Nagashima, K. A.; Kennedy, B. J.; Kang, Y. K.; Arrigale, R. R.; Donovan, G. P.; Magargal, W. W.; Maddon, P. J.; Olson, W. C. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J. Infect. Dis. 2012, 206, 706-713.
22. Davies, N. L.; Compson, J. E.; Mackenzie, B.; O'Dowd, V. L.; Oxbrow, A. K.; Heads, J. T.; Turner, A.; Sarkar, K.; Dugdale, S. L.; Jairaj, M.; et al. Lightwood DJ, Humphreys DP. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin. Vaccine Immunol. 2013, 20, 377-390.
23. Demarest, S. J.; Hariharan, M.; Elia, M.; Salbato, J.; Jin, P.; Bird, C.; Short, J. M.; Kimmel, B. E.; Dudley, M.; Woodnutt, G.; et al. Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs 2010, 2, 190-198.
24. Shreffler, W. G.; Lencer, D. A.; Bardina, L.; Sampson, H. A. IgE and IgG4 epitope mapping by microarray immunoassay reveals the diversity of immune response to the peanut allergen, Ara h 2. J. Allergy Clin. Immunol. 2005, 116, 893-899.
25. Kim, P.-H.; Iaconis, J. P.; Rolfe, R. D. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect. Immun. 1987, 55, 2984-2992.
26. Lyerly, D. M.; Bostwick, E. F.; Binion, S. B.; Wilkins, T. D. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect. Immunol. 1991, 59, 2215-2218.
27. Bostwick, E. F.; Hoerr, R. A. Therapeutic treatment of Clostridium difficile associated diseases. US Patent 5, 773, 000, 1998.
28. Van Dissel, J. T.; de Groot, N.; Hensgens, C. M.; Numan, S.; Kuijper, E. J.; Veldkamp, P.; van't Wout, J. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: Preclinical and preliminary clinical data. J. Med. Microbiol. 2005, 54, 197-205.
29. Hussack, G.; Tanha, J. Toxin-specific antibodies for the treatment of Clostridium difficile: Current status and future perspectives. Toxins (Basel) 2010, 2, 998-1018.
30. Leung, D. Y.; Kelly, C. P.; Boguniewicz, M.; Pothoulakis, C.; LaMont, J. T.; Flores, A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J. Pediatr. 1991, 118, 633-637.
31. Beales, I. L. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut 2002, 51, 456.
32. Wilcox, M. H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J. Antimicrob. Chemoth. 2004, 53, 882-884.
33. McPherson, S.; Rees, C. J.; Ellis, R.; Soo, S.; Panter, S. J. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis. Colon Rectum. 2006, 49, 640-645.
34. Cone, L. A.; Lopez, C.; Tarleton, H. L.; Jodoin, D.; Taylor, M.; Gade-Andavolu, R.; Dreisbach, L. P. A durable response to relapsing Clostridium difficile colitis may require combined therapy with high-dose oral vancomycin and intravenous immune globulin. Infect. Dis. Clin. Pract. 2006, 14, 217-220.
35. Juang, P.; Skledar, S. J.; Zgheib, N. K.; Paterson, D. L.; Vergis, E. N.; Shannon, W. D.; Ansani, N. T.; Branch, R. A. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am. J. Infect. Control. 2007, 35, 131-137.
36. Abougergi, M. S.; Broor, A.; Cui, W.; Jaar, B. G. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: An observational study and review of the literature. J. Hosp. Med. 2010, 5, E1-E9.
37. Humphreys, D. P.; Wilcox, M. H. Antibodies for treatment of Clostridium difficile infection. Clin. Vaccine Immunol. 2014, 21, 913-923.
38. Tjellstrom, B.; Stenhammar, L.; Eriksson, S.; Magnusson, K. E. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet 1993, 341, 701-702.
39. Saturno, E. J.; Costa, H.; Sorensen, R. Oral immunoglobulin therapy in a child with severe Clostridium Difficile diarrhea. J. Allergy Clin. Immunol. 2006, 117, S284 (abstract and poster).
40. BB-IND 3852. Bovine Immunoglobulin Concentrate, Clostridium difficile; Serial Number 022 Annual Report; U. S. Food and Drug Administration: Silver Spring, MD, USA, 1999.
41. Mattila, E.; Anttila, V. J.; Broas, M.; Marttila, H.; Poukka, P.; Kuusisto, K.; Pusa, L.; Sammalkorpi, K.; Dabek, J.; Koivurova, O. P.; et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: Efficacy and safety data of a prematurely interrupted trial. Scand. J. Infect. Dis. 2008, 40, 702-708.
42. Bauer, M. P.; Numan-Ruberg, S. C.; Bredewold, O. W.; Kuijper, E. J.; Mooi-Kokenberg, E. A.; Debast, S. B.; van Dissel, J. T. Recidieven van Clostridium difficile-geassocieerde diarree voorkómen door toediening van een weiconcentraat van specifiek geïmmuniseerde koeien; prospectief onderzoek [Recurrence of Clostridium difficile-associated diarrhoea prevented by the administration of a whey concentrate from specifically immunised cows; prospective study]. Ned. Tijdschr. Geneeskd 2008, 152, 1919-1926.
43. Stelwagen, K.; Carpenter, E.; Haigh, B.; Hodgkinson, A.; Wheeler, T. T. Immune components of bovine colostrum and milk. J. Anim. Sci. 2009, 87 (Suppl. 13), 3-9.
44. Roos, N.; Mahé, S.; Benamouzig, R.; Sick, H.; Rautureau, J.; Tomé, D. 15N-labeled immunoglobulins from bovine colostrum are partially resistant to digestion in human intestine. J. Nutr. 1995, 125, 1238-1244.
45. Stubbe, H.; Berdoz, J.; Kraehenbuhl, J.-P.; Corthesy, B. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile Toxin A damaging of T84 monolayers. J. Immunol. 2000, 164, 1952-1960.
46. Johnson, S.; Sypura, W. D.; Gerding, D. N.; Ewing, S. L.; Janoff, E. N. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect. Immun. 1995, 63, 3166-3173.
47. Lindh, E. Increased resistance of immunoglobulin A dimers to proteolytic degradation after binding of secretory component. J. Immunol. 1975, 114, 284-286.
48. Kyne, L.; Warny, M.; Qamar, A.; Kelly, C. P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against Toxin A. N. Engl. J. Med. 2000, 342, 390-397.
49. Kyne, L.; Warny, M.; Qamar, A.; Kelly, C. P. Association between antibody response to to toxin A and protection against recurrent Clostridium difficile Diarrhoea. Lancet 2001, 357, 189-193.
50. Hassoun, A.; Ibrahim, F. Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. Am. J. Geriatr. Pharmacother. 2007, 5, 48-51.
51. Jodlowski, T. Z.; Oehler, R.; Kam, L. W.; Melnychuk, I. Emerging Therapies in the Treatment of Clostridium difficile-Associated Disease. Ann. Pharmacother. 2006, 40, 2164-2169.
52. Haun, M.; Incledon, B.; Alles, P.; Wasi, S. A rapid procedure for the purification of IgA1 and IgA2 subclasses from normal human serum using protein G and jackfruit lectin (jacalin) affinity chromatography. Immunol. Lett. 1989, 22, 273-279.
53. Kabir, S. Jacalin: A jackfruit (Artocarpus heterophyllus) seed-derived lectin of versatile applications in immunobiological research. J. Immunol. Methods 1998, 212, 193-211.
54. Perrier, C.; Sprenger, N.; Corthésy, B. Glycans on secretory component participate in innate protection against mucosal pathogens. J. Biol. Chem. 2006, 281, 14280-14287.